View in EDS HTML Full Text PDF Full Text

Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).

Saved in:
Bibliographic Details
Title: Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).
Authors: Strati P; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Agajanian R; The Oncology Institute of Hope and Innovation, Downey, California, USA., Lossos IS; Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida, USA., Coleman M; Clinical Research Alliance/Weill Cornell Medicine, New York, New York, USA., Kridel R; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Wood A; AstraZeneca, Cambridge, UK., Lesley R; AstraZeneca, South San Francisco, California, USA., Wun CC; AstraZeneca, South San Francisco, California, USA., Stephens DM; University of North Carolina Lineberger Cancer Center, Chapel Hill, North Carolina, USA.
Source: British journal of haematology [Br J Haematol] 2025 Mar; Vol. 206 (3), pp. 887-898. Date of Electronic Publication: 2024 Dec 12.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39667721
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Strati+P%22">Strati P</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Agajanian+R%22">Agajanian R</searchLink>; The Oncology Institute of Hope and Innovation, Downey, California, USA.<br /><searchLink fieldCode="AU" term="%22Lossos+IS%22">Lossos IS</searchLink>; Sylvester Comprehensive Cancer Center, University of Miami-Miller School of Medicine, Miami, Florida, USA.<br /><searchLink fieldCode="AU" term="%22Coleman+M%22">Coleman M</searchLink>; Clinical Research Alliance/Weill Cornell Medicine, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Kridel+R%22">Kridel R</searchLink>; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Wood+A%22">Wood A</searchLink>; AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Lesley+R%22">Lesley R</searchLink>; AstraZeneca, South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Wun+CC%22">Wun CC</searchLink>; AstraZeneca, South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Stephens+DM%22">Stephens DM</searchLink>; University of North Carolina Lineberger Cancer Center, Chapel Hill, North Carolina, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220372544%22">British journal of haematology</searchLink> [Br J Haematol] 2025 Mar; Vol. 206 (3), pp. 887-898. <i>Date of Electronic Publication: </i>2024 Dec 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0372544 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1365-2141 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200071048%22">00071048 </searchLink><i>NLM ISO Abbreviation: </i>Br J Haematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39667721
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/bjh.19951
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 887
    Titles:
      – TitleFull: Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Strati P
      – PersonEntity:
          Name:
            NameFull: Agajanian R
      – PersonEntity:
          Name:
            NameFull: Lossos IS
      – PersonEntity:
          Name:
            NameFull: Coleman M
      – PersonEntity:
          Name:
            NameFull: Kridel R
      – PersonEntity:
          Name:
            NameFull: Wood A
      – PersonEntity:
          Name:
            NameFull: Lesley R
      – PersonEntity:
          Name:
            NameFull: Wun CC
      – PersonEntity:
          Name:
            NameFull: Stephens DM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2025 Mar
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1365-2141
          Numbering:
            – Type: volume
              Value: 206
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: British journal of haematology
              Type: main
ResultId 1